Cover Image

Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT : brief report

Enteropathy-associated T-cell lymphoma (EATL) is a rare subtype of peripheral T-cell lymphomas with a poor prognosis. Autologous stem cell transplantation (ASCT) was retrospectively evaluated as a consolidation or salvage strategy for EATL. The analysis included 44 patients who received ASCT for EAT...

Full description

Saved in:
Bibliographic Details
Main Authors: Jantunen, Esa (Author) , Boumendil, Ariane (Author) , Finel, Herve (Author) , Luan, Jian-Jian (Author) , Johnson, Peter (Author) , Rambaldi, Alessandro (Author) , Haynes, Andrew (Author) , Duchosal, Michel A. (Author) , Bethge, Wolfgang (Author) , Biron, Pierre (Author) , Carlson, Kristina (Author) , Craddock, Charles (Author) , Rudin, Claudius (Author) , Finke, Jurgen (Author) , Salles, Gilles (Author) , Kroschinsky, Frank (Author) , Sureda, Anna (Author) , Dreger, Peter (Author)
Format: Article (Journal)
Language:English
Published: January 29, 2013
In: Blood
Year: 2013, Volume: 121, Issue: 13, Pages: 2529-2532
ISSN:1528-0020
DOI:10.1182/blood-2012-11-466839
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood-2012-11-466839
Get full text
Author Notes:Esa Jantunen, Ariane Boumendil, Herve Finel, Jian-Jian Luan, Peter Johnson, Alessandro Rambaldi, Andrew Haynes, Michel A. Duchosal, Wolfgang Bethge, Pierre Biron, Kristina Carlson, Charles Craddock, Claudius Rudin, Jurgen Finke, Gilles Salles, Frank Kroschinsky, Anna Sureda, and Peter Dreger, on behalf of the Lymphoma Working Party of the EBMT
Description
Summary:Enteropathy-associated T-cell lymphoma (EATL) is a rare subtype of peripheral T-cell lymphomas with a poor prognosis. Autologous stem cell transplantation (ASCT) was retrospectively evaluated as a consolidation or salvage strategy for EATL. The analysis included 44 patients who received ASCT for EATL between 2000 and 2010. Thirty-one patients (70%) were in first complete or partial remission at the time of the ASCT. With a median follow-up of 46 months, relapse incidence, progression-free survival, and overall survival were 39%, 54%, and 59% at 4 years, respectively, with only one relapse occurring beyond 18 months posttransplant. There was a trend for better survival in patients transplanted in first complete or partial remission at 4 years (66% vs 36%; P = .062). ASCT is feasible in selected patients with EATL and can yield durable disease control in a significant proportion of the patients.
Item Description:Gesehen am 25.03.2021
Physical Description:Online Resource
ISSN:1528-0020
DOI:10.1182/blood-2012-11-466839

Similar Items